Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
1.020
0.00 (0.00%)
Apr 23, 2026, 4:00 PM EDT - Market closed
Genprex Employees
Genprex had 13 employees as of December 31, 2025. The number of employees decreased by 3 or -18.75% compared to the previous year.
Employees
13
Change
-3
Growth
-18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,248,381
Market Cap
9.39M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 13 | -3 | -18.75% | 13 | 0 |
| Sep 30, 2025 | 13 | -6 | -31.58% | 13 | 0 |
| Jun 30, 2025 | 15 | -6 | -28.57% | 15 | 0 |
| Mar 31, 2025 | 15 | -11 | -42.31% | 15 | 0 |
| Dec 31, 2024 | 16 | -10 | -38.46% | 16 | 0 |
| Sep 30, 2024 | 19 | -12 | -38.71% | 19 | 0 |
| Jun 30, 2024 | 21 | -9 | -30.00% | 21 | 0 |
| Dec 31, 2023 | 26 | -2 | -7.14% | 26 | 0 |
| Sep 30, 2023 | 31 | 9 | 40.91% | 31 | 0 |
| Jun 30, 2023 | 30 | 8 | 36.36% | 30 | 0 |
| Mar 31, 2023 | 28 | 9 | 47.37% | 28 | 0 |
| Dec 31, 2022 | 28 | 11 | 64.71% | 28 | 0 |
| Sep 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Jun 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Mar 31, 2022 | 19 | 7 | 58.33% | 19 | 0 |
| Dec 31, 2021 | 17 | 5 | 41.67% | 17 | 0 |
| Sep 30, 2021 | 16 | 4 | 33.33% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| BioAtla | 41 |
| BioLineRx | 24 |
| Bolt Biotherapeutics | 23 |
| CalciMedica | 16 |
| Kiora Pharmaceuticals | 13 |
| NuCana | 12 |
| Aprea Therapeutics | 8 |
GNPX News
- 1 day ago - Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting - PRNewsWire
- 2 days ago - Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy - PRNewsWire
- 3 days ago - Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - PRNewsWire
- 5 weeks ago - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - PRNewsWire
- 6 weeks ago - Genprex to Participate at BIO Europe Spring 2026 - PRNewsWire
- 2 months ago - Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - PRNewsWire
- 2 months ago - Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - PRNewsWire
- 3 months ago - Genprex Provides Clinical Update on Diabetes Gene Therapy Program - PRNewsWire